Medtronic is on track to raise its quarterly dividend for the 48th consecutive year, a streak that underscores the company’s commitment to returning capital to shareholders. The next increase, expected in the coming months, will mark nearly half a century of uninterrupted dividend growth—a record that places Medtronic among the longest-running Dividend Aristocrats in the medical technology sector. The company’s strong cash flow generation and disciplined capital allocation have enabled this consistency, even as it invests in research and development and strategic acquisitions.

Two of Medtronic’s fastest-growing franchises—Pulsed Field Ablation (PFA) for the treatment of atrial fibrillation and the Symplicity renal denervation system for hypertension—have been major contributors to recent top-line growth. In the latest reported quarter, PFA procedure volumes rose by more than 30% year-over-year, while Symplicity system shipments increased 45%, driven by expanded reimbursement coverage in Europe and Asia. These franchises now account for approximately 8% of the company’s overall revenue, underscoring their strategic importance in driving mid-single-digit organic revenue growth over the next two years.

S&P Global Ratings affirmed Medtronic’s corporate credit rating at A with a stable outlook, reflecting the company’s solid liquidity position and conservative leverage metrics. As of the end of the most recent quarter, Medtronic held roughly $8.5 billion in cash and short-term investments against $19.2 billion of total debt, translating to a net debt-to-EBITDA ratio near 2.2x. The stable outlook indicates that rating agency analysts expect the company to maintain free cash flow generation above $5 billion annually, sufficient to fund dividends, share repurchases, and bolt-on acquisitions without compromising financial flexibility.

In December 2025, Medtronic issued a notification to health care facilities to remove certain Left Heart Vent Catheters from use and sale due to reports that these catheters may fail to hold their designed shape when bent. While no patient fatalities have been linked to this issue, Medtronic recorded eight device malfunctions and two serious injuries related to catheter deformation during insertion procedures. The company has instructed customers to quarantine remaining inventory, return affected units for credit, and has initiated a corrective design review with its manufacturing partners to address the material properties of the catheter shaft.